Biotechnology · Immunology · Translational research
Founder & CEO, Rubhu Biologics Inc.
A Ph.D.-trained biochemist whose work spans cancer chemotherapy, HIV and immune biology, biologics development, cell therapy, and biotechnology leadership.
01 / Profile
Dr. Surendra J. Chavan is identified in the supplied record as a biotechnology researcher and executive. His published and institutional trail connects IIT Bombay and ACTREC in Mumbai with Memorial Sloan Kettering, North Shore University Hospital, industrial drug-development programs, and Rubhu Biologics in Athens, Georgia.
His work has moved through cancer chemotherapy, HIV immunology, molecular immune assays, biotherapeutics, cell therapy, and biotechnology-company leadership. The profile below is grounded in the supplied institutional, scholarly, patent, archived-company, and professional records.
M.Sc. Biotechnology, IIT Bombay; Ph.D. Biochemistry (cancer chemotherapy), Cancer Research Institute / ACTREC, University of Mumbai, completed 1993.
Postdoctoral research at Memorial Sloan Kettering Cancer Center is documented in the supplied institutional biography.
02 / Research
Early research
Early cancer research includes work on chronic myeloid leukemia cells, vitamin K3 and Adriamycin, P-glycoprotein-mediated multidrug resistance, and antitumor metal complexes. It provides the cancer-chemotherapy foundation described for the Ph.D. period.
ACTREC biography; 1991–1993 research publications1990s–2000s
The record connects Dr. Chavan with HIV reverse-transcriptase assay development, lymphocyte apoptosis, the effects of indinavir, T-cell-receptor excision circles, and clinical immune-reconstitution measures in HIV.
1995, 1999, 2001, and 2005 scholarly publications; institutional biographyCeltaxsys-era work
Patent material documents methods aimed at modulating the negative chemotaxis of immune cells. The supplied dossier describes related efforts to understand tumor-derived chemorepellant signals and support immune-cell migration toward tumors.
U.S. patent records; supplied research dossierRecent focus
The current scientific direction across Rubhu-related material includes cell characterization, potency and mechanism-of-action studies, immunogenicity and immunotoxicity, and support for T/NK, pancreatic-islet, mesenchymal-stem-cell, and iPSC-related programs.
Archived company-services material; scholarly affiliations2026
A 2026 Journal of Pharmaceutical Sciences review co-authored by Surendra Chavan describes an “ImmunoScore” framework for quantifying immune responses across vaccines, cancer immunity, autoimmunity, and anti-drug-antibody monitoring.
PubMed-indexed 2026 publication
03 / Selected experience
Dates and roles are presented as a source-aware professional record. Entries with limited corroboration are explicitly marked.
Mumbai, India
M.Sc. training in biotechnology at IIT Bombay was followed by a Ph.D. in biochemistry focused on cancer chemotherapy at the Cancer Research Institute, now ACTREC at Tata Memorial Centre. The supplied dossier links this period to multidrug resistance, vitamin K3, and platinum/palladium antitumor-complex research.
Institutional biography and research recordsNew York, NY
The ACTREC biography credits this period with a novel HIV reverse-transcriptase purification method. A 1995 analytical-biochemistry paper supports co-authorship on a fluorescent reverse-transcriptase assay.
Institutional biography; scholarly publicationManhasset, NY
The supplied ACTREC biography identifies a Clinical Director role in the Pediatric HIV Immunology Laboratory. PubMed-indexed work independently places Surendra Chavan with North Shore affiliations on HIV immune-reconstitution and T-cell-repertoire research.
Institutional biography; PubMed-indexed publicationsSan Diego, CA
The supplied career material places him in drug-development roles involving biologics, monoclonal antibodies, fusion proteins, preclinical work, and cellular-immunotherapy development.
Institutional biography and self-reported career chronologyAtlanta, GA
Led research described as targeting immune-cell trafficking and negative chemotaxis. Patent records substantiate Celtaxsys-linked work on modulating negative chemotaxis of immune cells, while the precise title and dates are drawn from the supplied chronology.
Patent records; institutional biography; self-reported chronologyGeorgia, USA
Listed in an aggregator-derived career chronology as a pharmaceutical and biologics consulting leadership role. This entry is retained for completeness but has not been independently reconciled in the supplied material.
Single-source / unconfirmed career recordNavi Mumbai, India
A 2013 ACTREC Alumni Association brochure identifies him as CTO and co-founder of QuantImmune Solutions. The supplied career history later associates him with Accutest Biologics and bioanalytical work for biologics and biosimilars.
Dated ACTREC Alumni material; career chronologyAthens / Suwanee, GA
The record associates this role with localized immune and inflammatory-response modulation and islet-cell approaches for Type 1 diabetes.
Career chronology; public talk contextAthens, GA
Company archival material, supplied LinkedIn material, and 2026 scholarly affiliations consistently associate Dr. Chavan with Rubhu Biologics. The organization is presented as a research and development support facility for biologics and cellular therapies.
Archived company pages; LinkedIn; 2026 scholarly affiliationsUnited States / international
The extended dossier describes advisory work on life-science software, preclinical-to-clinical strategy, regulatory submissions, CRO review, and quality systems. These recent roles are included as supplied dossier claims.
Extended dossier / not independently audited here04 / Record at a glance
Every figure below is a direct count of the itemised rows in this dossier. The site lists 9, 10 and 12+ patents and "50+" publications as supplied totals; those aggregates are not reconciled here and are deliberately excluded from these charts.
05 / Rubhu Biologics
Rubhu Biologics is described in archived company material as a biologics drug-development support and research facility in Athens, Georgia.
The capability descriptions here are historical, archived company statements—not a representation that every service is currently available or connected to an approved product.
Cell and biochemical characterization in support of biologics and cellular-therapy programs.
Cell-based potency assays, in-vitro bioassays, and mechanism-of-action studies.
Immunological, immunogenicity, immunotoxicity, immune-cell, and receptor-repertoire analyses.
Assay development and validation; purity, viability, impurity, pharmacokinetic, and stability studies.
Material references T-cell, NK-cell, pancreatic-islet, mesenchymal-stem-cell, and iPSC therapies.
Archived services material references cGMP/cGDP quality systems and FDA IND/BLA support.
Histology, immunohistochemistry, and immunofluorescence are among the listed support areas.
Archived material includes manufacturing, shipment, and stability-study support.
06 / Innovation record
The supplied files contain inconsistent aggregate counts. Individual, source-labeled records are more useful than an unverified total.
Rubhu Biologics Inc.
Names Surendra Jagannath Chavan as inventor and describes red-blood-cell-based cryopreservation compositions intended to improve post-thaw viability. A filing is not evidence of clinical use, regulatory approval, or commercialization.
Google Patents recordRubhu Biologics Inc.
International counterpart covering compositions using red blood cells, antibodies, and cryoprotectants for biological-material preservation. It should not be described as an issued international patent.
WIPO / Google Patents recordOriginally assigned to Celtaxsys, Inc.
Lists Surendra Chavan, Jonathan L. Moon, and Lopa Bhatt as inventors. The patent addresses immune-cell migration toward cancer cells by inhibiting tumor-released chemorepellants; later assignment activity means the original-assignee wording is deliberate.
U.S. patent recordCeltaxsys, Inc.
An earlier Celtaxsys-linked application naming Surendra Chavan, consistent with the industrial research record but not, on its own, proof of an exact employment title.
U.S. patent application recordPatent record
Names Surendra Chavan and addresses immune-cell chemotaxis, inflammation, angiogenesis, and tumor-related applications. Exact person-level attribution is less certain than the Celtaxsys-linked records.
U.S. patent application record; identity caution notedPatent record
Describes reactivation of resting harvested T cells shortly before infusion. The supplied record treats it as potentially relevant but flags the absence of an employer-level identity link.
U.S. patent application record; identity caution notedCeltaxsys / Rubhu-related dossier entries
The extended dossier also lists US 2014/0294862 A1, US 2016/0199470 A1, WO 2023/049619 A1, US 2025/0032640 A1, and WO 2004/027052 A1. They are preserved in the local research archive; the selected cards above are the individually documented records in the supplied evidence review.
Extended HTML dossierJournal of Pharmaceutical Sciences · I. Gopallawa, S. Chavan, A. Goswami, V. Jawa, N. Chirmule
ImmunoScore framework; Rubhu Biologics affiliationJournal of Pharmaceutical Sciences · Five-author collaboration including Surendra Chavan
Authorship and Rubhu affiliation corroborationClinical Immunology · Surendra Chavan and collaborators
Immune-cell profiling and assay developmentThe Journal of Infectious Diseases · H. Zhang, S. Chavan, and collaborators
TREC markers and immune reconstitutionBlood · S. Chavan, S. Kodoth, R. Pahwa, S. Pahwa
HIV pharmacology and lymphocyte cell-cycle effectsClinical Immunology · Surendra J. Chavan and collaborators
HIV disease and T-cell apoptosisAIDS Research & Human Retroviruses · T. W. McCloskey, S. Chavan, and collaborators
Lymphocyte cell-death measurementAnalytical Biochemistry · S. J. Chavan, H. J. Prochaska
Fluorescent reverse-transcriptase activity assayJournal of Cellular Biochemistry / BBRC · H. J. Prochaska, S. Chavan, and collaborators
HIV transcription and replicationCancer chemotherapy / inorganic-biochemistry literature · S. Chavan and ACTREC collaborators
Cancer chemotherapy and antitumor chemistryNo publication in the selected record matches that search.
07 / Scientific exchange
An institutional media archive records this invited talk and its connection to Vicapsys work in cell therapy for Type 1 diabetes.
Georgia Tech media archiveA conference program lists Surendra J. Chavan of QuantImmune Solutions in a keynote forum focused on immunogenicity in biotherapeutics.
Conference scientific programThe college introduction presents Dr. Chavan as a founder and CEO with a biotechnology, cell-based-therapy, and biotherapeutics background. Transcript naming is imperfect, so the identification is contextual.
Official video recording; contextual identificationThe extended dossier reports talks, course contributions, and conference participation involving therapeutic cell manufacturing, biologics, biosimilars, and biotechnology entrepreneurship. These entries remain available in the local source archive.
Extended dossier / mixed-source evidence08 / Evidence & provenance
This site separates strong cross-supported evidence from self-reported, archival, and secondary-source claims. It preserves the supplied research set locally while avoiding unsupported or sensitive information in the public-facing profile.
The source set identifies the subject as a Ph.D.-trained biochemist and biotechnology scientist. It does not establish an MD, MBBS, medical residency, or clinical-licensure credential; the site therefore does not characterize him as a physician.
The profile is matched through the distinctive IIT Bombay + ACTREC education, North Shore HIV research, Celtaxsys/QuantImmune/Rubhu history, and Athens context. Other people named Surendra Chavan—including a pharma consultant, mountaineer, political candidate, designer, and unrelated corporate professionals—are excluded.
Supplied materials variously report 9, 10, 12+, or more patent filings, and 50+ publications or citation totals. Because those aggregate counts are not reconciled by an itemized authoritative list, this site prioritizes individually named patents and selected publications rather than a single headline total.
The career sequence combines institutional biographies, scholarly affiliations, patent records, archived pages, and a self-reported LinkedIn chronology. Some dates overlap; timeline entries describe the supplied record rather than assert a fully audited, non-overlapping employment history.
Rubhu capability statements are drawn from archived official pages. They document what the company described historically and should not be read as confirmation that every service remains available, independently validated, or tied to an approved clinical product.
One supplied text file contains a generic clinician-administrator and patient-care narrative that conflicts with the stronger biotechnology evidence. It is retained in the local research archive for provenance, but it is intentionally not used as biographical fact.
The source archive is preserved locally, while personal-contact and unrelated-person material is not republished in the public profile. External links point to the cited professional and scholarly sources.
Local, source-aware database
